Latham Biopharm Group

Executive Summary

Latham BioPharm Group (LBG) is a Boston-based life sciences consulting firm founded in 2018, specializing in drug delivery, biologics, vaccines, and cell and gene therapies. The company offers strategic planning, product development, and non-dilutive funding services to biotech, pharma, and medical device companies. By focusing on complex challenges in these high-growth areas, LBG positions itself as a valuable partner for clients navigating the intricacies of drug development and regulatory pathways. Given its established presence and specialized expertise, LBG is well-poised to benefit from the continued expansion of the biologics and cell and gene therapy markets. As a private consulting firm, its growth is driven by client engagements and repeat business. While the company does not have publicly disclosed financial metrics or major R&D catalysts typical of drug developers, its success hinges on its reputation and ability to secure new contracts. The outlook is stable but not high-growth, as the consulting sector generally sees moderate organic expansion.

Upcoming Catalysts (preview)

• TBDLandmark client engagement with a top-20 pharma company30% success
• TBDExpansion into new therapy area (e.g., RNA therapeutics)40% success
• TBDStrategic partnership with a contract development and manufacturing organization (CDMO)50% success